Outfitter Financial LLC Has $631,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Outfitter Financial LLC lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,970 shares of the medical equipment provider’s stock after buying an additional 460 shares during the quarter. Outfitter Financial LLC’s holdings in Zimmer Biomet were worth $631,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. BLB&B Advisors LLC grew its holdings in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after buying an additional 100 shares in the last quarter. CKW Financial Group grew its stake in shares of Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after acquiring an additional 100 shares in the last quarter. FWG Holdings LLC increased its position in Zimmer Biomet by 2.9% during the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after acquiring an additional 101 shares during the period. Romano Brothers AND Company raised its stake in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after purchasing an additional 102 shares in the last quarter. Finally, Financial Advocates Investment Management boosted its holdings in Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after purchasing an additional 103 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ZBH shares. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Barclays cut their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Up 0.3 %

Shares of ZBH opened at $103.64 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The stock has a market capitalization of $20.63 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 1.95 and a beta of 1.02. The stock has a fifty day moving average of $105.90 and a 200-day moving average of $107.48.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm posted $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.93%. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.